Aura Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aura Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-94.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 81% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-26.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 61% of Healthcare companies in United States.
Cash Cushion Ratio
+19%Cash, after subtracting all debt, equals 19% of its market value (net cash).
Higher than 61% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Aura Biosciences, Inc. made a loss over the last year. Aura Biosciences, Inc. owes $0.09 for every $1 it owns. Aura Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAura Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.12The share price is 2.12 times Aura Biosciences, Inc.'s book value per share, lower than 56% of Healthcare companies in United States.
Market cap
$670 MThe total market value of all of Aura Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 59% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$315 MWhat Aura Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.04Net worth divided by the number of shares. The share price of $6.46 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-53.5%Aura Biosciences, Inc. lost 53.5% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
Owes vs Owns
0.09×Aura Biosciences, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Dividend yield
NoneAura Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossAura Biosciences, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashAura Biosciences, Inc. held $127 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aura Biosciences, Inc.: $670 M ÷ $315 M (30 Jun 2026) = 2.1.
What is Aura Biosciences, Inc.'s return on equity?
Aura Biosciences, Inc. lost 53.5% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
How much does Aura Biosciences, Inc. owe compared with what it owns?
Aura Biosciences, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Does Aura Biosciences, Inc. pay a dividend?
No. Aura Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.